SCHEMBL1394237

SCHEMBL1394237

O=c1[nH]c2ccccc2cc1I

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DAO P14920 2/20 0.60
BRD4 O60885 1/20 0.60
DDO Q99489 1/20 0.60
KDR P35968 2/20 0.56
CHEK1 O14757 1/20 0.56
GRIN2D O15399 2/20 0.54
GRIN3B O60391 2/20 0.54
GRIN1 Q05586 2/20 0.54
GRIN2A Q12879 2/20 0.54
GRIN2B Q13224 2/20 0.54
GRIN2C Q14957 2/20 0.54
GRIN3A Q8TCU5 2/20 0.54
KDM4E B2RXH2 4/20 0.50
PDGFRB P09619 1/20 0.49
FGFR1 P11362 1/20 0.49
FLT3 P36888 1/20 0.47
CYP2A6 P11509 1/20 0.47
AOC3 Q16853 2/20 0.47
CA12 O43570 1/20 0.47
CA1 P00915 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29573445 1.00 DAO (0.60) DAOBRD4DDOKDRCHEK1
SCHEMBL4460778 0.75 DAO (0.60) DAOBRD4DDOKDRCHEK1
SCHEMBL10617 0.75 DAO (0.60) DAOBRD4DDOKDRCHEK1
SCHEMBL10481645 0.75 DAO (0.60) DAOBRD4DDOKDRCHEK1
SCHEMBL248620 0.75 BRD4 (1.00) DAOBRD4DDOKDRCHEK1
SCHEMBL1625559 0.75 DAO (0.60) DAOBRD4DDOKDRCHEK1
SCHEMBL10285239 0.75 DAO (0.60) DAOBRD4DDOKDRCHEK1
SCHEMBL6283609 0.75 DAO (0.60) DAOBRD4DDOKDRCHEK1
SCHEMBL1582138 0.75 DAO (0.60) DAOBRD4DDOKDRCHEK1
SCHEMBL545302 0.75 DAO (0.60) DAOBRD4DDOKDRCHEK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2025106863-A1 LACTAM DERIVATIVES FOR INHIBITING NLRP3 AND USES THEREOF VENTUS THERAPEUTICS U.S., INC. (US) 2025-05-22 WO disclosed
US-9206131-B2 Compounds having antiparasitic or anti-infectious activity OREGON HEALTH & SCIENCE UNIVERSITY (US) 2015-12-08 US disclosed
WO-2015050379-A1 NOVEL QUINOLINONE DERIVATIVE AND USE THEREOF 광주과학기술원 2015-04-09 WO disclosed
EP-2205590-B1 CGRP ANTAGONISTS BOEHRINGER INGELHEIM INT (DE) 2014-06-04 EP disclosed
US-20140045888-A1 COMPOUNDS HAVING ANTIPARASITIC OR ANTI-INFECTIOUS ACTIVITY OREGON HEALTH & SCIENCE UNIVERSITY (US) 2014-02-13 US disclosed
US-8598354-B2 Compounds having antiparasitic or anti-infectious activity UNIVERSITY OF SOUTH FLORIDA (US) 2013-12-03 US disclosed
WO-2012167237-A2 COMPOUNDS HAVING ANTIPARASITIC OR ANTI-INFECTIOUS ACTIVITY MEDICINES FOR MALARIA VENTURE (CH) 2012-12-06 WO disclosed
US-20120115904-A1 COMPOUNDS HAVING ANTIPARASITIC OR ANTI-INFECTIOUS ACTIVITY OREGON HEALTH & SCIENCE UNIVERSITY 2012-05-10 US disclosed
US-20120010237-A1 COMPOUNDS HAVING ANTIPARASITIC OR ANTI-INFECTIOUS ACTIVITY THE GOVERNMENT OF THE UNITED STATES OF AMERICA DBA THE DEPARTMENT OF VETERANS AFFAIRS 2012-01-12 US disclosed
US-20080274107-A1 Tyrosine kinase inhibitors MERCK SHARP & DOHME CORP. 2008-11-06 US disclosed
EP-1496982-A2 SOLID FORMS OF SALTS WITH TYROSINE KINASE ACTIVITY Merck & Co., Inc. (US) 2003-10-30 EP disclosed
EP-1328519-A2 ORALLY ACTIVE SALTS WITH TYROSINE KINASE ACTIVITY Merck & Co., Inc. (US) 2003-07-23 EP disclosed
WO-2003037252-A2 TYROSINE KINASE INHIBITORS MERCK & CO., INC. (US) 2003-05-08 WO disclosed
WO-2003020276-A1 TYROSINE KINASE INHIBITORS MERCK & CO., INC. (US) 2003-03-13 WO disclosed
WO-2003020699-A2 TYROSINE KINASE INHIBITORS MERCK & CO., INC. (US) 2003-03-13 WO disclosed
EP-1226136-A2 TYROSINE KINASE INHIBITORS Merck & Co., Inc. (US) 2002-07-31 EP disclosed
US-20020072526-A1 Orally active salts with tyrosine kinase activity MERCK & CO., INC. 2002-06-13 US disclosed
WO-2002032861-A2 ORALLY ACTIVE SALTS WITH TYROSINE KINASE ACTIVITY MERCK & CO., INC. (US) 2002-04-25 WO disclosed
US-6306874-B1 ENZYME INHIBITORS SUCH AS ANGIOGENESIS, CANCER, TUMOR GROWTH, ATHEROSCLEROSIS, AGE RELATED MACULAR DEGENERATION, DIABETIC RETINOPATHY, INFLAMMATORY DISEASES, AND THE LIKE IN MAMMALS. MERCK & CO., INC. 2001-10-23 US disclosed
WO-2001029025-A2 TYROSINE KINASE INHIBITORS MERCK & CO., INC. (US) 2001-04-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120010237-A1 COMPOUNDS HAVING ANTIPARASITIC OR ANTI-INFECTIOUS ACTIVITY MASTL, RPS10, CBR3 DAO 64/4885BRD4 795/4885DDO 1061/4885
US-20140045888-A1 COMPOUNDS HAVING ANTIPARASITIC OR ANTI-INFECTIOUS ACTIVITY H1-10, RAB10, HDAC10 DAO 35/4885BRD4 2978/4885DDO 426/4885
US-20020072526-A1 Orally active salts with tyrosine kinase activity TEK, FLT1, TIE1 DAO 2182/4885BRD4 1805/4885DDO 2569/4885
US-20120115904-A1 COMPOUNDS HAVING ANTIPARASITIC OR ANTI-INFECTIOUS ACTIVITY H1-10, RAB10, HDAC10 DAO 38/4885BRD4 2976/4885DDO 417/4885
US-20080274107-A1 Tyrosine kinase inhibitors ERBB2, TYRO3, TIE1 DAO 1113/4885BRD4 2180/4885DDO 1750/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.